Document Detail


Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India.
MedLine Citation:
PMID:  23045961     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
Authors:
Shanmugam Saravanan; Vidya Madhavan; Pachamuthu Balakrishnan; Davey M Smith; Sunil Suhas Solomon; Sathasivam Sivamalar; Selvamuthu Poongulali; Nagalingeswaran Kumarasamy; Robert T Schooley; Suniti Solomon; Rami Kantor
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-12-07
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  29     ISSN:  1931-8405     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-26     Completed Date:  2013-08-02     Revised Date:  2014-09-26    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  630-2     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use*
Cross-Sectional Studies
Drug Resistance, Viral*
HIV Infections / drug therapy*,  virology*
HIV Protease / genetics
HIV Protease Inhibitors / therapeutic use
HIV-1 / drug effects*,  isolation & purification
Humans
India
Mutation, Missense
Sulfonamides / therapeutic use*
Grant Support
ID/Acronym/Agency:
AI047745/AI/NIAID NIH HHS; AI080353/AI/NIAID NIH HHS; AI100665/AI/NIAID NIH HHS; AI36214/AI/NIAID NIH HHS; AI69432/AI/NIAID NIH HHS; AI74621/AI/NIAID NIH HHS; DA034978/DA/NIDA NIH HHS; DP1 DA034978/DA/NIDA NIH HHS; K24 AI100665/AI/NIAID NIH HHS; MH097520/MH/NIMH NIH HHS; MH62512/MH/NIMH NIH HHS; MH83552/MH/NIMH NIH HHS; P30 MH062512/MH/NIMH NIH HHS; R01 MH097520/MH/NIMH NIH HHS; R01AI66922/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/HIV Protease Inhibitors; 0/Sulfonamides; EC 3.4.23.-/HIV Protease; YO603Y8113/darunavir
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with ...
Next Document:  Magnetic Resonance Properties of Gd(III)-Bound Lipid-Coated Microbubbles and their Cavitation Fragme...